Picard Medical Reports Q1 Revenue of $1.1M Driven by Increased STAH Utilization
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Apr 22 2026
0mins
Should l Buy PMI?
Source: seekingalpha
- Revenue Growth: Picard Medical reported Q1 revenue of $1.1 million, reflecting a significant increase compared to the previous year, indicating rising demand for heart medical devices in the market.
- Increased Utilization: The higher utilization of the SynCardia Total Artificial Heart directly contributed to revenue growth, showcasing the company's technological advantage and market acceptance in cardiac treatment.
- Rental Income Boost: The increase in driver rental income further strengthened the company's financial performance, indicating growing customer reliance on its devices and laying a foundation for future revenue growth.
- Positive Market Outlook: With the rising number of heart disease patients, demand for Picard Medical's products is expected to continue growing, and the company's strategic positioning in the cardiac medical field will further solidify its market presence.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy PMI?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on PMI
About PMI
Picard Medical, Inc. is a holding company that owns a 100% interest in SynCardia Systems, LLC (SynCardia). SynCardia is a medical technology company that manufactures and sells the only United States Food and Drug Administration (FDA) and Health Canada-approved implantable total artificial heart (SynCardia TAH). The SynCardia TAH is a biventricular replacement device that consists of the SynCardia TAH implant, an external pneumatic driver that delivers precisely calibrated pulses of air to drive the implant, and drivelines that connect the driver to the implant. The SynCardia TAH implant is a system that consists of two independent artificial ventricles which are powered by an external pneumatic driver. Each artificial ventricle is made of a semi-rigid polyurethane housing and a rigid polyurethane base, with a four-layer flexible polyurethane diaphragm separating the blood chamber from the air chamber.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Picard Medical Reports Q1 Revenue of $1.1M Driven by Increased STAH Utilization
- Revenue Growth: Picard Medical reported Q1 revenue of $1.1 million, reflecting a significant increase compared to the previous year, indicating rising demand for heart medical devices in the market.
- Increased Utilization: The higher utilization of the SynCardia Total Artificial Heart directly contributed to revenue growth, showcasing the company's technological advantage and market acceptance in cardiac treatment.
- Rental Income Boost: The increase in driver rental income further strengthened the company's financial performance, indicating growing customer reliance on its devices and laying a foundation for future revenue growth.
- Positive Market Outlook: With the rising number of heart disease patients, demand for Picard Medical's products is expected to continue growing, and the company's strategic positioning in the cardiac medical field will further solidify its market presence.
See More
Picard Medical Participates in ISHLT 2026 Annual Meeting
- Conference Participation: Picard Medical will showcase its latest fully implantable artificial heart technology at the ISHLT 2026 Annual Meeting on April 24, 2026, highlighting the company's ongoing innovation in treating heart and lung diseases.
- Technology Presentation: Andre R. Simon, Vice President of Clinical Affairs at SynCardia, will present a poster on the 'Emperor Total Artificial Heart,' emphasizing the development progress of the next-generation fully implantable heart platform, which is expected to attract significant attention from clinical experts.
- Industry Impact: Participation in the conference not only demonstrates Picard Medical's engagement with the global clinical community but also underscores the company's commitment to advancing innovation in mechanical circulatory support through scientific exchange and collaboration, potentially enhancing its market position.
- Global Network: SynCardia's artificial heart technology has been implanted over 2,100 times across 27 countries, making it the most widely used and extensively studied artificial heart globally, further solidifying its leadership in the heart disease treatment market.
See More
Class Action Lawsuit Reminder Against Picard Medical, Inc.
- Class Action Notification: The Schall Law Firm reminds investors of a class action lawsuit against Picard Medical, Inc. (NYSE American:PMI) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934, concerning securities purchased between September 2, 2025, and October 31, 2025.
- False Statement Allegations: The complaint alleges that Picard made false and misleading statements to the market, engaging in a manipulation scheme to fraudulently inflate its share price, resulting in investor losses when the truth emerged.
- Investor Rights Protection: Affected investors are encouraged to contact the Schall Law Firm before April 13, 2026, to participate in the lawsuit and seek compensation, noting that the class has not yet been certified, leaving investors unrepresented until then.
- Legal Consultation Services: The Schall Law Firm offers free legal consultations, allowing investors to discuss their rights and understand the steps to participate in the lawsuit via phone or email.
See More
Faruqi & Faruqi Encourages Picard Medical Investors to Reach Out
- Legal Investigation Initiated: Faruq & Faruqi, LLP is investigating potential claims against Picard Medical, particularly for investors who purchased securities between September 2, 2025, and October 31, 2025, highlighting the firm's commitment to protecting investor rights.
- Investor Contact Information: Partner Josh Wilson encourages affected investors to reach out directly at 877-247-4292 or 212-983-9330 (Ext. 1310), providing a clear legal consultation channel to help investors understand their rights.
- Class Action Deadline: The firm reminds investors that the deadline to seek the role of lead plaintiff in the federal securities class action against Picard Medical is April 13, 2026, emphasizing the importance of timely action to safeguard investor legal rights.
- Role of Securities Law Firm: As a leading national securities law firm, Faruqi & Faruqi's investigation indicates potential legal risks for Picard Medical, urging investors to stay informed about the situation to assess potential losses and legal options.
See More
Picard Medical Securities Class Action Reminder
- Class Action Notice: Rosen Law Firm reminds investors who purchased Picard Medical (NYSE American: PMI) securities between September 2 and October 31, 2025, to apply as lead plaintiffs by April 13, 2026, to participate in the class action and seek compensation.
- Fee Arrangement: Investors joining the class action will incur no upfront costs, as the law firm operates on a contingency fee basis, meaning investors bear no financial risk until compensation is secured, thus enhancing accessibility to legal recourse.
- Lawsuit Background: The lawsuit alleges that Picard Medical failed to disclose significant adverse facts related to its business and securities trading during the class period, including fraudulent stock promotions via social media and insider trading activities, which may have led to investor losses.
- Law Firm Credentials: Rosen Law Firm specializes in securities class actions, having recovered over $438 million for investors in 2019 alone, and was ranked first by ISS Securities Class Action Services in 2017, demonstrating its extensive experience and success in handling such cases.
See More
Picard Medical Securities Class Action Notice
- Class Action Deadline: Purchasers of Picard Medical (NYSE: PMI) securities are reminded that April 13, 2026, is the deadline to apply as lead plaintiff, and failure to do so will forfeit participation in the lawsuit.
- Lawsuit Background: The lawsuit alleges that Picard Medical's management failed to disclose significant adverse facts regarding the company's business and securities trading from September 2 to October 31, 2025, misleading investors.
- Fraud Allegations Uncovered: The lawsuit claims that Picard Medical was involved in a fraudulent stock promotion scheme using social media misinformation, with insiders allegedly using offshore accounts to manipulate stock prices, severely impacting investor decisions and market confidence.
- Legal Counsel Advisory: The Rosen Law Firm advises investors to select qualified legal counsel with a proven track record in class actions to ensure adequate legal support in the lawsuit, cautioning against choosing firms that merely act as intermediaries.
See More
Picard Medical Reports Q1 Revenue of $1.1M Driven by Increased STAH Utilization
- Revenue Growth: Picard Medical reported Q1 revenue of $1.1 million, reflecting a significant increase compared to the previous year, indicating rising demand for heart medical devices in the market.
- Increased Utilization: The higher utilization of the SynCardia Total Artificial Heart directly contributed to revenue growth, showcasing the company's technological advantage and market acceptance in cardiac treatment.
- Rental Income Boost: The increase in driver rental income further strengthened the company's financial performance, indicating growing customer reliance on its devices and laying a foundation for future revenue growth.
- Positive Market Outlook: With the rising number of heart disease patients, demand for Picard Medical's products is expected to continue growing, and the company's strategic positioning in the cardiac medical field will further solidify its market presence.
See More
Picard Medical Participates in ISHLT 2026 Annual Meeting
- Conference Participation: Picard Medical will showcase its latest fully implantable artificial heart technology at the ISHLT 2026 Annual Meeting on April 24, 2026, highlighting the company's ongoing innovation in treating heart and lung diseases.
- Technology Presentation: Andre R. Simon, Vice President of Clinical Affairs at SynCardia, will present a poster on the 'Emperor Total Artificial Heart,' emphasizing the development progress of the next-generation fully implantable heart platform, which is expected to attract significant attention from clinical experts.
- Industry Impact: Participation in the conference not only demonstrates Picard Medical's engagement with the global clinical community but also underscores the company's commitment to advancing innovation in mechanical circulatory support through scientific exchange and collaboration, potentially enhancing its market position.
- Global Network: SynCardia's artificial heart technology has been implanted over 2,100 times across 27 countries, making it the most widely used and extensively studied artificial heart globally, further solidifying its leadership in the heart disease treatment market.
See More
Class Action Lawsuit Reminder Against Picard Medical, Inc.
- Class Action Notification: The Schall Law Firm reminds investors of a class action lawsuit against Picard Medical, Inc. (NYSE American:PMI) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934, concerning securities purchased between September 2, 2025, and October 31, 2025.
- False Statement Allegations: The complaint alleges that Picard made false and misleading statements to the market, engaging in a manipulation scheme to fraudulently inflate its share price, resulting in investor losses when the truth emerged.
- Investor Rights Protection: Affected investors are encouraged to contact the Schall Law Firm before April 13, 2026, to participate in the lawsuit and seek compensation, noting that the class has not yet been certified, leaving investors unrepresented until then.
- Legal Consultation Services: The Schall Law Firm offers free legal consultations, allowing investors to discuss their rights and understand the steps to participate in the lawsuit via phone or email.
See More
Faruqi & Faruqi Encourages Picard Medical Investors to Reach Out
- Legal Investigation Initiated: Faruq & Faruqi, LLP is investigating potential claims against Picard Medical, particularly for investors who purchased securities between September 2, 2025, and October 31, 2025, highlighting the firm's commitment to protecting investor rights.
- Investor Contact Information: Partner Josh Wilson encourages affected investors to reach out directly at 877-247-4292 or 212-983-9330 (Ext. 1310), providing a clear legal consultation channel to help investors understand their rights.
- Class Action Deadline: The firm reminds investors that the deadline to seek the role of lead plaintiff in the federal securities class action against Picard Medical is April 13, 2026, emphasizing the importance of timely action to safeguard investor legal rights.
- Role of Securities Law Firm: As a leading national securities law firm, Faruqi & Faruqi's investigation indicates potential legal risks for Picard Medical, urging investors to stay informed about the situation to assess potential losses and legal options.
See More
Picard Medical Securities Class Action Reminder
- Class Action Notice: Rosen Law Firm reminds investors who purchased Picard Medical (NYSE American: PMI) securities between September 2 and October 31, 2025, to apply as lead plaintiffs by April 13, 2026, to participate in the class action and seek compensation.
- Fee Arrangement: Investors joining the class action will incur no upfront costs, as the law firm operates on a contingency fee basis, meaning investors bear no financial risk until compensation is secured, thus enhancing accessibility to legal recourse.
- Lawsuit Background: The lawsuit alleges that Picard Medical failed to disclose significant adverse facts related to its business and securities trading during the class period, including fraudulent stock promotions via social media and insider trading activities, which may have led to investor losses.
- Law Firm Credentials: Rosen Law Firm specializes in securities class actions, having recovered over $438 million for investors in 2019 alone, and was ranked first by ISS Securities Class Action Services in 2017, demonstrating its extensive experience and success in handling such cases.
See More
Picard Medical Securities Class Action Notice
- Class Action Deadline: Purchasers of Picard Medical (NYSE: PMI) securities are reminded that April 13, 2026, is the deadline to apply as lead plaintiff, and failure to do so will forfeit participation in the lawsuit.
- Lawsuit Background: The lawsuit alleges that Picard Medical's management failed to disclose significant adverse facts regarding the company's business and securities trading from September 2 to October 31, 2025, misleading investors.
- Fraud Allegations Uncovered: The lawsuit claims that Picard Medical was involved in a fraudulent stock promotion scheme using social media misinformation, with insiders allegedly using offshore accounts to manipulate stock prices, severely impacting investor decisions and market confidence.
- Legal Counsel Advisory: The Rosen Law Firm advises investors to select qualified legal counsel with a proven track record in class actions to ensure adequate legal support in the lawsuit, cautioning against choosing firms that merely act as intermediaries.
See More
